Excerpts: Hemispherx presentation on Ampligen, XMRV, Nov 18, 2010

[JohnnyD]

This is a nicely detailed summary of an investor conference, with all the other Hemispherx programs (flu, cancer) excerpted out.

http://www.facebook.com/note.php?note_id=469940716796&comments&ref=mf

One additional thing that was said on Tuesday, the 16th, during a Quarterly conference call and that relates directly to the slide 12 bar graph in the link above -- is that Hemispherx thinks they have a therapeutic surrogate marker for XMRV->CFS. IOW, patients that test positive, respond best. WPI is culturing their 516 trial participants and they only have about 10-15% of the data they want. They figure they need 60-85% of the data to approach the FDA again. A peer reviewed CFS/QT interval paper should be published very soon.

 

[Rooney]

From where will this extra data come? There are so very few current trial participants, if Hunter-Hopkins in Charlotte is any indication. Any ideas on this?

Thanks Johnny D.

 

[JohnnyD]

Hi Rooney,

This is retrospective analysis of their completed AMP516 pivotal trial. The 516 trial ended well before the WPI discovered the XMRV/CFS association. With WPI's help, they are doing serology and culture on the 516 participants and then comparing that data to how well the ampligen arm did on the ETT (Exercise Tolerance Test).